{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:02:38Z","timestamp":1789664558319,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","award":["LCSuPaC 30"],"award-info":[{"award-number":["LCSuPaC 30"]}],"id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer cachexia causes significant morbidity and mortality in advanced lung cancer patients. Clinical benefit of \u03b2-hydroxy-\u03b2-methylbutyrate, arginine, and glutamine (HMB\/Arg\/Gln) was assessed in newly diagnosed patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      NOURISH, a prospective, two-arm, open-label, multi-centre, randomised controlled phase II trial compared cachexia in patients who received HMB\/Arg\/Gln with those who did not. All patients received structured nutritional, exercise and symptom control via a Macmillan Durham Cachexia Pack. Conducted in five UK centres, patients aged\n                      <jats:underline>&gt;<\/jats:underline>\n                      \u200918\u2009years, with newly diagnosed advanced small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), who were able to take oral nutrition, with a performance status of 0-to-2 and a life expectancy &gt;\u20094\u2009months were eligible for trial entry. Patients suitable for treatment with curative intent were ineligible. The trial was designed as a signal-seeking pilot study with target recruitment of 96 patients. One-to-one randomisation was stratified by diagnosis (SCLC or NSCLC), stage of disease (locally advanced or metastatic) and performance status. The primary outcome measure was treatment success defined as a patient being alive without significant loss of lean body mass (not &gt;\u20095%) by 12\u2009weeks. Secondary outcome measures included quality of life.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between February-2012 and February-2013, 38 patients were recruited, 19 to each arm. Baseline characteristics were balanced. The trial was halted due to slow accrual and partial adherence. Trial data demonstrated no evidence of treatment benefit. No serious adverse events were reported during the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Further evaluation of HMB\/Arg\/Gln in this setting could not be recommended on the basis of this trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      ISRCTN registry: 39911673; 14-Apr-2011\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"https:\/\/doi.org\/10.1186\/ISRCTN39911673\">10.1186\/ISRCTN39911673<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08519-8","type":"journal-article","created":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T22:02:26Z","timestamp":1626040946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Beta-hydroxy beta-methylbutyrate\/arginine\/glutamine (HMB\/Arg\/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)"],"prefix":"10.1186","volume":"21","author":[{"given":"Jennifer","family":"Pascoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Gaskell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gaunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-4262","authenticated-orcid":false,"given":"Lucinda","family":"Billingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"issue":"1","key":"8519_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","volume":"1","author":"S von Haehling","year":"2010","unstructured":"von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1(1):1\u20135. https:\/\/doi.org\/10.1007\/s13539-010-0002-6.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"8519_CR2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1177\/1534735418781743","volume":"17","author":"J S\u00f8rensen","year":"2018","unstructured":"S\u00f8rensen J. Lung cancer cachexia: can molecular understanding guide clinical management? Integr Cancer Ther. 2018;17(3):1000\u20138. https:\/\/doi.org\/10.1177\/1534735418781743.","journal-title":"Integr Cancer Ther"},{"issue":"11","key":"8519_CR3","doi-asserted-by":"publisher","first-page":"S227","DOI":"10.1016\/j.ejso.2016.07.050","volume":"42","author":"A Hug","year":"2016","unstructured":"Hug A, Phillips I, Allan L, Ezhil V. Rate of cachexia in lung cancer. Eur J Surg Oncol (EJSO). 2016;42(11):S227. https:\/\/doi.org\/10.1016\/j.ejso.2016.07.050.","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"5","key":"8519_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8519_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jcsm.12253","volume":"9","author":"DS Mytelka","year":"2018","unstructured":"Mytelka DS, Li L, Benoit K. Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer. J Cachexia Sarcopenia Muscle. 2018;9(1):86\u201392. https:\/\/doi.org\/10.1002\/jcsm.12253.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"8519_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-2407-10-50","volume":"10","author":"O Arrieta","year":"2010","unstructured":"Arrieta O, Michel Ortega RM, Villanueva-Rodr\u00edguez G, Serna-Thom\u00e9 MG, Flores-Estrada D, Diaz-Romero C, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer. 2010;10:50.","journal-title":"BMC Cancer"},{"issue":"4","key":"8519_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0959-8049(97)10090-9","volume":"34","author":"HJN Andreyev","year":"1998","unstructured":"Andreyev HJN, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34(4):503\u20139. https:\/\/doi.org\/10.1016\/S0959-8049(97)10090-9.","journal-title":"Eur J Cancer"},{"issue":"1","key":"8519_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/1759-7714.12910","volume":"10","author":"R Zhu","year":"2019","unstructured":"Zhu R, Liu Z, Jiao R, Zhang C, Yu Q, Han S, et al. Updates on the pathogenesis of advanced lung cancer-induced cachexia. Thorac Cancer. 2019;10(1):8\u201316. https:\/\/doi.org\/10.1111\/1759-7714.12910.","journal-title":"Thorac Cancer"},{"issue":"11","key":"8519_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JOP.2016.016832","volume":"12","author":"AR Bruggeman","year":"2016","unstructured":"Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. Cancer Cachexia: beyond weight loss. J Oncol Pract. 2016;12(11):1163\u201371. https:\/\/doi.org\/10.1200\/JOP.2016.016832.","journal-title":"J Oncol Pract"},{"issue":"3","key":"8519_CR10","first-page":"CD004310-CD","volume":"2013","author":"V Ruiz Garcia","year":"2013","unstructured":"Ruiz Garcia V, L\u00f3pez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;2013(3):CD004310-CD.","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"8519_CR11","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","volume":"24","author":"F Strasser","year":"2006","unstructured":"Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the cannabis-in-cachexia-study-group. J Clin Oncol. 2006;24(21):3394\u2013400. https:\/\/doi.org\/10.1200\/JCO.2005.05.1847.","journal-title":"J Clin Oncol"},{"issue":"29","key":"8519_CR12","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1200\/JCO.2013.54.3926","volume":"32","author":"\u00d8 Paulsen","year":"2014","unstructured":"Paulsen \u00d8, Klepstad P, Rosland JH, Aass N, Albert E, Fayers P, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014;32(29):3221\u20138. https:\/\/doi.org\/10.1200\/JCO.2013.54.3926.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8519_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/0284186X.2012.724536","volume":"52","author":"TS Solheim","year":"2013","unstructured":"Solheim TS, Fearon KCH, Blum D, Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol. 2013;52(1):6\u201317. https:\/\/doi.org\/10.3109\/0284186X.2012.724536.","journal-title":"Acta Oncol"},{"issue":"4","key":"8519_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/gut.2004.047563","volume":"54","author":"JN Gordon","year":"2005","unstructured":"Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54(4):540\u20135. https:\/\/doi.org\/10.1136\/gut.2004.047563.","journal-title":"Gut."},{"issue":"4","key":"8519_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(15)00558-6.","journal-title":"Lancet Oncol"},{"issue":"8","key":"8519_CR16","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","volume":"28","author":"D Currow","year":"2017","unstructured":"Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017;28(8):1949\u201356. https:\/\/doi.org\/10.1093\/annonc\/mdx192.","journal-title":"Ann Oncol"},{"issue":"3","key":"8519_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124(3):606\u201316. https:\/\/doi.org\/10.1002\/cncr.31128.","journal-title":"Cancer."},{"issue":"3","key":"8519_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00000658-200209000-00013","volume":"236","author":"JZ Williams","year":"2002","unstructured":"Williams JZ, Abumrad N, Barbul A. Effect of a specialized amino acid mixture on human collagen deposition. Ann Surg. 2002;236(3):369\u201375. https:\/\/doi.org\/10.1097\/00000658-200209000-00013.","journal-title":"Ann Surg"},{"issue":"4","key":"8519_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00726-010-0678-0","volume":"40","author":"NE Zanchi","year":"2011","unstructured":"Zanchi NE, Gerlinger-Romero F, Guimar\u00e3es-Ferreira L, de Siqueira Filho MA, Felitti V, Lira FS, et al. HMB supplementation: clinical and athletic performance-related effects and mechanisms of action. Amino Acids. 2011;40(4):1015\u201325. https:\/\/doi.org\/10.1007\/s00726-010-0678-0.","journal-title":"Amino Acids"},{"issue":"1","key":"8519_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/1568008013341811","volume":"1","author":"MA Potenza","year":"2001","unstructured":"Potenza MA, Nacci C, Mitolo-Chieppa D. Immunoregulatory effects of L-arginine and therapeutical implications. Curr Drug Targets Immune Endocr Metabol Disord. 2001;1(1):67\u201377. https:\/\/doi.org\/10.2174\/1568008013341811.","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"8519_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.2741\/3707","volume":"16","author":"P Xi","year":"2011","unstructured":"Xi P, Jiang Z, Zheng C, Lin Y, Wu G. Regulation of protein metabolism by glutamine: implications for nutrition and health. Front Biosci (Landmark Ed). 2011;16:578\u201397.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"6","key":"8519_CR22","doi-asserted-by":"publisher","first-page":"E1409","DOI":"10.1152\/ajpendo.90530.2008","volume":"295","author":"HL Eley","year":"2008","unstructured":"Eley HL, Russell ST, Tisdale MJ. Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by beta-hydroxy-beta-methylbutyrate. Am J Physiol Endocrinol Metab. 2008;295(6):E1409\u201316. https:\/\/doi.org\/10.1152\/ajpendo.90530.2008.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"8519_CR23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.clnu.2013.02.011","volume":"32","author":"NEP Deutz","year":"2013","unstructured":"Deutz NEP, Pereira SL, Hays NP, Oliver JS, Edens NK, Evans CM, et al. Effect of \u03b2-hydroxy-\u03b2-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. Clin Nutr. 2013;32(5):704\u201312. https:\/\/doi.org\/10.1016\/j.clnu.2013.02.011.","journal-title":"Clin Nutr"},{"issue":"10","key":"8519_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00520-008-0403-7","volume":"16","author":"L Berk","year":"2008","unstructured":"Berk L, James J, Schwartz A, Hug E, Mahadevan A, Samuels M, et al. A randomized, double-blind, placebo-controlled trial of a \u03b2-hydroxyl \u03b2-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer. 2008;16(10):1179\u201388. https:\/\/doi.org\/10.1007\/s00520-008-0403-7.","journal-title":"Support Care Cancer"},{"issue":"4","key":"8519_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0002-9610(02)00823-1","volume":"183","author":"PE May","year":"2002","unstructured":"May PE, Barber A, D\u2019Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of \u03b2-hydroxy-\u03b2-methylbutyrate, arginine, and glutamine. Am J Surg. 2002;183(4):471\u20139. https:\/\/doi.org\/10.1016\/S0002-9610(02)00823-1.","journal-title":"Am J Surg"},{"key":"8519_CR26","unstructured":"Macmillan Cancer Support. 2007. Macmillan Durham Cachexia Pack. https:\/\/learnzone.org.uk\/courses\/course.php?id=67 Last accessed 10th May 2015."},{"issue":"Suppl 1","key":"8519_CR27","doi-asserted-by":"publisher","first-page":"A112","DOI":"10.1136\/bmjspcare-2012-000196.330","volume":"2","author":"C Hawkins","year":"2012","unstructured":"Hawkins C, Andrew I. Raising awareness of the Macmillan Durham Cachexia pack (MDCP) within a local cancer network. BMJ Support Palliat Care. 2012;2(Suppl 1):A112.","journal-title":"BMJ Support Palliat Care"},{"key":"8519_CR28","unstructured":"The Scored Patient-Generated Subjective Global Assessment. http:\/\/pt-global.org\/?page_id=13 Last accessed 16th March 2021."},{"issue":"10","key":"8519_CR29","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1023\/A:1016670403148","volume":"9","author":"JM Ribaudo","year":"2000","unstructured":"Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Roenn JV, et al. Re-validation and shortening of the functional Assessmentof anorexia\/Cachexia therapy (FAACT) questionnaire. Qual Life Res. 2000;9(10):1137\u201346. https:\/\/doi.org\/10.1023\/A:1016670403148.","journal-title":"Qual Life Res"},{"issue":"4","key":"8519_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/sim.2961","volume":"27","author":"S-H Jung","year":"2008","unstructured":"Jung S-H. Randomized phase II trials with a prospective control. Stat Med. 2008;27(4):568\u201383. https:\/\/doi.org\/10.1002\/sim.2961.","journal-title":"Stat Med"},{"issue":"6","key":"8519_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1200\/JOP.2013.000996","volume":"9","author":"TW LeBlanc","year":"2013","unstructured":"LeBlanc TW, Lodato JE, Currow DC, Abernethy AP. Overcoming recruitment challenges in palliative care clinical trials. J Oncol Pract. 2013;9(6):277\u201382. https:\/\/doi.org\/10.1200\/JOP.2013.000996.","journal-title":"J Oncol Pract"},{"key":"8519_CR32","doi-asserted-by":"publisher","unstructured":"White R, Weekes CE, Grant R, Baldwin C, Ahmed H. Determining the prevalence and severity of cancer cachexia in advanced non-small cell lung cancer and its relationship with chemotherapy outcomes. Support Care Cancer. 2020. https:\/\/doi.org\/10.1007\/s00520-019-5259-1.","DOI":"10.1007\/s00520-019-5259-1"},{"issue":"9","key":"8519_CR33","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1007\/s00520-018-4175-4","volume":"26","author":"T Yokota","year":"2018","unstructured":"Yokota T, Hamauchi S, Yoshida Y, Yurikusa T, Suzuki M, Yamashita A, et al. A phase II study of HMB\/Arg\/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer. Support Care Cancer. 2018;26(9):3241\u20138. https:\/\/doi.org\/10.1007\/s00520-018-4175-4.","journal-title":"Support Care Cancer"},{"issue":"9","key":"8519_CR34","first-page":"251","volume":"30","author":"N Wada","year":"2018","unstructured":"Wada N, Kurokawa Y, Tanaka K, Miyazaki Y, Makino T, Takahashi T, et al. Perioperative nutritional support with beta-hydroxy-beta-methylbutyrate, arginine, and glutamine in surgery for abdominal malignancies. Wounds. 2018;30(9):251\u20136.","journal-title":"Wounds."},{"issue":"3","key":"8519_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/bmjspcare-2017-001440","volume":"8","author":"TS Solheim","year":"2018","unstructured":"Solheim TS, Laird BJA, Balstad TR, Bye A, Stene G, Baracos V, et al. Cancer cachexia: rationale for the MENAC (multimodal-exercise, nutrition and anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018;8(3):258\u201365. https:\/\/doi.org\/10.1136\/bmjspcare-2017-001440.","journal-title":"BMJ Support Palliat Care"},{"issue":"3","key":"8519_CR36","doi-asserted-by":"publisher","first-page":"e042883","DOI":"10.1136\/bmjopen-2020-042883","volume":"11","author":"L Buonaccorso","year":"2021","unstructured":"Buonaccorso L, Bertocchi E, Autelitano C, Allisen Accogli M, Denti M, Fugazzaro S, et al. Psychoeducational and rehabilitative intervention to manage cancer cachexia (PRICC) for patients and their caregivers: protocol for a single-arm feasibility trial. BMJ Open. 2021;11(3):e042883. https:\/\/doi.org\/10.1136\/bmjopen-2020-042883.","journal-title":"BMJ Open"},{"issue":"1","key":"8519_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12937-020-00657-2","volume":"20","author":"A Molassiotis","year":"2021","unstructured":"Molassiotis A, Brown T, Cheng HL, Byrnes A, Chan RJ, Wyld D, et al. The effects of a family-centered psychosocial-based nutrition intervention in patients with advanced cancer: the PiCNIC2 pilot randomised controlled trial. Nutr J. 2021;20(1):2. https:\/\/doi.org\/10.1186\/s12937-020-00657-2.","journal-title":"Nutr J"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08519-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08519-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08519-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T22:03:54Z","timestamp":1626041034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08519-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8519"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08519-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-753663\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"25 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the trial protocol (ultimately Version 3.0 dated 02-April-2014) was obtained from the Black Country Research Ethics Committees (now West Midlands \u2013 The Black Country) and the following local institutional review boards: Sandwell and West Birmingham Hospitals NHS Trust \u2013 City Hospital; Heart of England NHS Foundation Trust - Birmingham Heartlands Hospital; University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital, and; The Dudley Group of Hospitals NHS Foundation Trust - Russells Hall Hospital. The trial was performed in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"800"}}